name: Respiratory virus detection by nucleic acid using amplified probe technique, 12-25 targets


name: Respiratory virus detection by nucleic acid using multiplex reverse transcription technique, 12-25 targets


name: Detection test by nucleic acid for respiratory syncytial virus, amplified probe technique


name: Respiratory syncytial virus detection by amplified nucleic acid probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique


name: Amplifed DNA or RNA probe detection of severe acute respiratory syndrome coronavirus 2 (Covid-19) antigen


name: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid by amplified DNA probe technique


name: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid by amplified RNA probe technique


name: Detection test by nucleic acid for Staphylococcus aureus (bacteria), amplified probe technique


name: Staphylococcus aureus detection by amplified nucleic acid probe technique


name: Detection test by nucleic acid for Staphylococcus aureus, methicillin resistant (MRSA bacteria), amplified probe technique


name: Methicillin resistant Staphylococcus aureus (MRSA) detection by amplified nucleic acid probe technique


name: Detection test by nucleic acid for Strep (Streptococcus, group A), amplified probe technique


name: Group A Streptococcus detection by amplified nucleic acid probe technique


name: Detection test by nucleic acid for Strep (Streptococcus, group A), quantification


name: Group A Streptococcus detection by nucleic acid using quantification


name: Detection test by nucleic acid for Strep (Streptococcus, group B), amplified probe technique


name: Group B Streptococcus detection by amplified nucleic acid probe technique


name: Trichomonas vaginalis detection by direct nucleic probe technique


name: Detection test by nucleic acid for Trichomonas vaginalis (genital parasite), amplified probe technique


name: Trichomonas vaginalis detection by amplified nucleic acid probe technique


name: Zika virus detection by amplified nucleic acid probe technique


name: Infectious agent detection by nucleic acid (not otherwise specified) using direct probe technique, each organism


name: Detection test by nucleic acid for organism, amplified probe technique


name: Infectious agent detection by nucleic acid (not other wise specified) using amplified probe technique, each organism


name: Detection test by nucleic acid for organism, quantification


name: Infectious agent (not otherwise specified) quantification by nucleic acid probe technique, each organism


name: Detection test by nucleic acid for multiple organisms, direct probe(s) technique


name: Infectious agent detection by nucleic acid using direct probe technique, multiple organisms


name: Infectious agent detection by nucleic acid using amplified probe technique, multiple organisms


name: Human immunodeficiency virus type 1 (HIV-1) antigen and HIV-1 and HIV-2 antibodies detection by immunoassay with direct optical observation


name: Human immunodeficiency virus type 1 (HIV-1) genotype analysis by nucleic acid of reverse transcriptase and protease regions


name: Analysis test by nucleic acid for Hepatitis C virus


name: Nucleic acid analysis of infectious agent genotype of hepatitis C (HepC) virus


name: Analysis test by nucleic acid for HIV-1 virus, other region


name: Human immunodeficiency virus type 1 (HIV-1) nucleic acid genotype analysis, other region


name: Analysis test by nucleic acid for cytomegalovirus, cytomegalovirus


name: Analysis test by nucleic acid for hepatitis b virus


name: Nucleic acid analysis of infectious agent genotype of hepatitis B (HepB) virus


name: Analysis test by nucleic acid for HIV-1 virus, first through 10 drugs tested


name: Human immunodeficiency virus type 1 (HIV-1) phenotype analysis by nucleic acid with drug resistance tissue culture analysis, first 1-10 drugs tested


name: Analysis test by nucleic acid for HIV-1 virus, each additional drug tested


name: Human immunodeficiency virus type 1 (HIV-1) phenotype analysis by nucleic acid with drug resistance tissue culture analysis, each additional drug tested


name: Analysis of non-viral infectious agent enzymatic activity


name: Gross necropsy with brain and spinal cord


name: Gross examination and necropsy with brain, for newborn


name: Gross examination and necropsy with brain, for stillborn


name: Gross and microscopic necropsy with brain and spinal cord


name: Gross and microscopic necropsy including brain, for infant


name: Gross and microscopic necropsy with brain, for newborn


name: Gross and microscopic necropsy with brain, for stillborn


name: Cytopathology on smear of fluid specimen (except cervical or vaginal) collected by brushing, with interpretation


name: Cytopathology on smear of fluid specimen (except cervical or vaginal) collected by washing, with interpretation


name: Cytopathology on smear of fluid specimen (except cervical or vaginal) collected by brushing using simple filter method, with interpretation


name: Cytopathology on smear of fluid specimen (except cervical or vaginal) collected by washing using simple filter method, with interpretation


name: Cell examination of specimen, concentration technique


name: Cytopathology by selective cellular enhancement technique and interpretation (excluding cervical or vaginal specimen)


name: Cytopathology on urinary tract specimen with manual morphometric analysis using in situ hybridization, 3-5 molecular probes


name: Cell examination of urine, computer-assisted


name: Cytopathology on urinary tract specimen with computer-assisted morphometric analysis using in situ hybridization, 3-5 molecular probes


name: Sex identification, peripheral blood smear


name: Cytopathology on cervical specimen with automated thin layer preparation and manual screening under physician supervision


name: Cytopathology on vaginal specimen with automated thin layer preparation and manual screening under physician supervision


name: Pap test, manual screening and rescreening


name: Cytopathology on cervical specimen with automated thin layer preparation, manual screening, and rescreening under physician supervision


name: Cytopathology on vaginal specimen with automated thin layer preparation, manual screening, and rescreening under physician supervision


name: Cytopathology on cervical smear with screening using automated system under physician supervision


name: Cytopathology on vaginal smear with screening using automated system under physician supervision


name: Pap test (Pap smear), automated system with manual rescreening


name: Cytopathology on cervical smear with screening using automated system and manual rescreening under physician supervision


name: Cytopathology on vaginal smear with screening using automated system and manual rescreening under physician supervision


name: Cytopathology on cervical smear with manual screening under physician supervision


name: Cytopathology on vaginal smear with manual screening under physician supervision


name: Pap test, slides, automated system with computer-assisted rescreening


name: Cytopathology on cervical smear with manual screening and computer-assisted rescreening under physician supervision


name: Cytopathology on vaginal smear with manual screening and computer-assisted rescreening under physician supervision


name: Pap test, slides, manual screening and rescreening


name: Cytopathology on cervical smear with manual screening and rescreening under physician supervision


name: Cytopathology on vaginal smear with manual screening and rescreening under physician supervision


name: Screening examination of specimen cells, preparation, screening and interpretation


name: Screening examination of specimen cells, extended study


name: Cytopathology smears any other source, extended study of 5 or more slides


name: Cytopathology smears any other source, extended study of 5 or more slides and multiple stains on smear


name: Cytopathology smears any other source, extended study of multiple stains on smear


name: Pap test, slides, manual screening (the Bethesda System)


name: Pap test, slides, manual screening and rescreening (the Bethesda System)


name: Cytopathology on cervical smear with manual screening and rescreening using Bethesda system under physician supervision


name: Cytopathology on vaginal smear with manual screening and rescreening using Bethesda system under physician supervision


name: Pap test, slides, manual screening and computer-assisted rescreening (the Bethesda System)


name: Cytopathology on cervical smear with manual screening and computer-assisted rescreening using Bethesda system under physician supervision


name: Cytopathology on vaginal smear with manual screening and computer-assisted rescreening using Bethesda system under physician supervision


name: Pap test, slides, manual screening and computer-assisted rescreening using cell selection (the Bethesda System)


name: Cytopathology on cervical smear with manual screening and computer-assisted rescreening using cell selection and review and using Bethesda system under physician supervision


name: Cytopathology on vaginal smear with manual screening and computer-assisted rescreening using cell selection and review and using Bethesda system under physician supervision


name: Pap test, automated thin layer preparation; automated system


name: Cytopathology on cervical specimen with automated thin layer preparation and screening using automated system under physician supervision


name: Cytopathology on vaginal specimen with automated thin layer preparation and screening using automated system under physician supervision


name: Pap test, automated thin layer preparation; automated system and manual rescreening


name: Cytopathology on cervical specimen with automated thin layer preparation and screening using automated system and manual rescreening under physician supervision


name: Cytopathology on vaginal specimen with automated thin layer preparation and screening using automated system and manual rescreening under physician supervision


name: Cytohistologic evaluation of fine needle aspirate to determine adequacy for diagnosis, first evaluation episode, each site


name: Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode


name: Cytohistologic evaluation of fine needle aspirate to determine adequacy for diagnosis, each separate additional evaluation episode, same site


name: Flow cytometry technique for DNA or cell analysis, first marker


name: Flow cytometry for detection of first cell surface marker


name: Flow cytometry for detection of first cytoplasmic marker


name: Flow cytometry for detection of first nuclear marker


name: Flow cytometry technique for DNA or cell analysis, each additional marker


name: Flow cytometry for detection of each additional cell surface marker


name: Flow cytometry for detection of each additional cytoplasmic marker


name: Flow cytometry for detection of each additional nuclear marker


name: Flow cytometry technique for DNA or cell analysis, 2 to 8 markers


name: Interpretation of flow cytometry, 2-8 markers


name: Flow cytometry technique for DNA or cell analysis, 9 to 15 markers


name: Interpretation of flow cytometry, 9-15 markers


name: Flow cytometry technique for DNA or cell analysis, 16 or more markers


name: Interpretation of flow cytometry, 16 or more markers


name: Tissue culture of lymphocytes for evaluation of non-neoplastic disorder


name: Tissue culture of skin biopsy for evaluation of non-neoplastic disorder


name: Tissue culture of tissue biopsy for evaluation of non-neoplastic disorder


name: Tissue culture of amniotic fluid cells for evaluation of non-neoplastic disorder


name: Tissue culture of chorionic villus cells for evaluation of non-neoplastic disorder


name: Chromosome analysis for genetic defects, baseline Sister Chromatid Exchange (SCE), 20-25 cells


name: Chromosome analysis for breakage syndrome using measurement of baseline Sister Chromatid Exchange (SCE), 20-25 cells


name: Chromosome analysis for genetic defects, baseline breakage, score 50-100 cells, count 20 cells


name: Chromosome analysis for breakage syndrome using measurement of baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes


name: Chromosome analysis for genetic defects, score 100 cells, clastogen stress


name: Chromosome analysis for genetic defects, count 5 cells


name: Chromosome analysis for genetic defects, count 15-20 cells


name: Chromosome analysis for genetic defects, count 45 cells for mosaicism


name: Chromosome analysis for mosaicism, count 45 cells from 2 karyotypes with banding


name: Chromosome analysis for genetic defects, analyze 20-25 cells


name: Chromosome analysis of amniotic fluid, count 15 cells from single karyotype with banding


name: Chromosome analysis of chorionic villus, count 15 cells from single karyotype with banding


name: Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, single karyotype, with banding


name: Molecular cytogenetics using DNA probe, each probe


name: Molecular cytogenetics using chromosomal in situ hybridization, 3-5 cells


name: Chromosome analysis for genetic defects, analyze 10-30 cells


name: Molecular cytogenetics using chromosomal in situ hybridization, 10-30 cells


name: Chromosome analysis for genetic defects, analyze 25-99 cells


name: Molecular cytogenetics using interphase in situ hybridization, 25-99 cells


name: Chromosome analysis for genetic defects, analyze 100-300 cells


name: Molecular cytogenetics using interphase in situ hybridization, 100-300 cells


name: Chromosome analysis for genetic defects, additional specialized banding technique


name: Chromosome analysis for genetic defects, additional cells counted, each study


name: Chromosome analysis for genetic defects, additional high resolution study


name: Surgical pathology with gross and microscopic examination of foreskin of newborn


name: Surgical pathology with gross and microscopic examination of foreskin (other than newborn)


name: Surgical pathology with gross and microscopic examination of specimen from biopsy of oropharynx


name: Surgical pathology with gross and microscopic examination of specimen from biopsy of urethra


name: Surgical pathology with gross and microscopic examination of specimen from resection of brain (other than for tumor)


name: Surgical pathology with gross and microscopic examination of specimen from resection of meninges (other than for tumor)


name: Surgical pathology with gross and microscopic examination of specimen from resection of ovary (non-neoplastic)


name: Surgical pathology with gross and microscopic examination of specimen from resection of ovary with fallopian tube (non-neoplastic)


name: Surgical pathology with gross and microscopic examination of specimen from skin (other than cyst, tag, debridement, and plastic repair)


name: Surgical pathology with gross and microscopic examination of specimen from soft tissue (other than tumor, mass, lipoma, and debridement)


name: Surgical pathology with gross and microscopic examination of specimen from testis (other than tumor, biopsy, and castration)


name: Surgical pathology with gross and microscopic examination of specimen from transbronchial biopsy of lung


name: Surgical pathology with gross and microscopic examination of specimen from uterine myomectomy for leiomyoma (without uterus)


name: Surgical pathology with gross and microscopic examination of specimen from extensive resection of soft tissue for neoplasm


name: Surgical pathology with gross and microscopic examination of specimen from partial resection of larynx with regional lymph nodes


name: Surgical pathology with gross and microscopic examination of specimen from subtotal resection of bladder


name: Surgical pathology with gross and microscopic examination of specimen from subtotal resection of vulva


name: Surgical pathology consultation and report on referred material requiring preparation of slides


name: Pathology examination of specimen during surgery, first tissue block


name: Intraoperative pathology examination with frozen section, single specimen


name: Pathology examination of specimen during surgery, each additional tissue block


name: Intraoperative pathology examination with frozen section, each additional specimen


name: Pathology cytologic examination of specimen during surgery, initial site


name: Intraoperative cytologic examination, initial site


name: Pathology cytologic examination of specimen during surgery, each additional site


name: Intraoperative cytologic examination, each additional site


name: Special stained specimen slides to examine tissue, each additional procedure


name: Immunocytochemistry per specimen for each additional single antibody stain procedure


name: Immunohistochemistry per specimen for each additional single antibody stain procedure


name: Special stained specimen slides to examine tissue, initial procedure


name: Immunocytochemistry per specimen for initial single antibody stain procedure


name: Immunohistochemistry per specimen for initial single antibody stain procedure


name: Immunocytochemistry per specimen for each multiplex antibody stain procedure


name: Immunohistochemistry per specimen for each multiplex antibody stain procedure


name: Antibody evaluation, initial single antibody stain procedure


name: Immunofluorescent study of antibody using direct method, per specimen of initial single antibody stain procedure


name: Antibody evaluation, each additional single antibody stain procedure


name: Antibody identification using immunofluorescence, each additional single antibody stain procedure


name: Microscopic genetic analysis of tumor, manual


name: Manual quantitative morphometric analysis of tumor immunohistochemistry, per specimen of each single antibody stain procedure


name: Manual semiquantitative morphometric analysis of tumor immunohistochemistry, per specimen of each single antibody stain procedure


name: Microscopic genetic analysis of tumor, using computer-assisted technology


name: Quantitative morphometric analysis of tumor immunohistochemistry using computer-assisted technology, per specimen of each single antibody stain procedure


name: Semiquantitative morphometric analysis of tumor immunohistochemistry using computer-assisted technology, per specimen of each single antibody stain procedure


name: Examination of archival tissue for genetic analysis


name: Genetic sequencing localization, each additional procedure


name: In situ hybridization, each additional single probe strain


name: Genetic sequencing localization, initial procedure


name: In situ hybridization, initial single probe stain


name: Genetic sequencing localization, each multiplex procedure


name: In situ hybridization, each multiplex probe stain


name: Quantitative morphometric analysis with in situ hybridization using computer-assisted technology, initial single probe strain


name: Semiquantitative morphometric analysis with in situ hybridization using computer-assisted technology, initial single probe strain


name: Quantitative morphometric analysis with in situ hybridization using computer-assisted technology, each additional single probe strain


name: Semiquantitative morphometric analysis with in situ hybridization using computer-assisted technology, each additional single probe strain


name: Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure


name: Quantitative morphometric analysis with in situ hybridization using computer-assisted technology, each multiplex probe strain


name: Semiquantitative morphometric analysis with in situ hybridization using computer-assisted technology, each multiplex probe strain


name: Microscopic genetic analysis of tissue, manual, initial procedure


name: Manual quantitative morphometric analysis with in situ hybridization, per specimen of initial single probe stain procedure


name: Manual semiquantitative morphometric analysis with in situ hybridization, per specimen of initial single probe stain procedure


name: Quantitative morphometric analysis with in situ hybridization, each additional single probe strain


name: Semiquantitative morphometric analysis with in situ hybridization, each additional single probe strain


name: Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure


name: Protein analysis of tissue by Western Blot with interpretation and report, each immunological probe for band identification


name: Real time optical endomicroscopic image interpretation and report, each endoscopic session


name: Referred optical endomicroscopic image interpretation and report, each endoscopic session


name: Macroscopic examination, dissection, and preparation of frozen section for analytical study with touch imprint


name: Macroscopic examination, dissection, and preparation of tissue for analytical study with frozen section


name: Macroscopic examination, dissection, and preparation of tissue for analytical study with touch imprint, each tissue preparation


name: Quantitative transcutaneous measurement of hemoglobin (Hgb)


name: Quantitative transcutaneous measurement of carboxyhemoglobin, per day


name: Hemoglobin measurement, per day, methemoglobin


name: Quantitative transcutaneous measurement of methemoglobin, per day


name: Caffeine halothane contracture test (CHCT) for malignant hyperthermia susceptibility with interpretation and report


name: Cell count and differential count on body fluid (except blood)


name: Crystal identification in body fluid (except urine) using light microscopy with polarizing lens analysis


name: Culture of embryo with embryo coculture, less than 4 days


name: Culture of oocyte with oocyte coculture, less than 4 days


name: Sperm identification from testicular aspirate (other than seminal fluid)


name: Simple preparation of sperm isolation with semen analysis for diagnosis


name: Simple preparation of sperm isolation with semen analysis for insemination


name: Complex preparation of sperm isolation with semen analysis for diagnosis


name: Complex preparation of sperm isolation with semen analysis for insemination


name: Assisted oocytes fertilization using microtechnique, 10 or fewer


name: Assisted oocyte fertilization (fertility procedure), greater than 10 oocytes


name: Assisted oocytes fertilization using microtechnique, 11 or more


name: Biopsy of embryo blastomere using microtechnique, 5 or fewer


name: Biopsy of oocyte polar body using microtechnique, 5 or fewer


name: Biopsy of embryo blastomere using microtechnique, 6 or more


name: Biopsy of oocyte polar body using microtechnique, 6 or more


name: Semen analysis with evaluation of sperm motility including Huhner test


name: Semen analysis with evaluation of sperm presence including Huhner test


name: Thawing of each aliquot of cryopreserved semen


name: Thawing of each aliquot of cryopreserved sperm


name: Thawing of each aliquot of cryopreserved oocytes


name: Human erythrocyte gene analysis of 35 antigens from 11 blood groups in whole blood, common red blood cell (RBC) alleles reported


name: Measurement of ascorbic acid, succinic acid, and carnitine in urine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps for colorectal oncology


name: ERG, PCA3, and SPDEF gene expression profile using real time reverse transcription polymerase chain reaction (RT-PCR) in urine specimen, algorithm reported as risk score for prostate cancer


name: Next-generation sequencing of DNA, 16S, and 23S rRNA, gyrA, pbp1, rdxA, and rpoB for detection of Helicobacter pylori and antibiotic resistance in fecal sample reported as positive or negative, to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin reported as positive or negative, to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin


name: Next-generation sequencing of DNA, 16S, and 23S rRNA, gyrA, pbp1, rdxA, and rpoB for detection of Helicobacter pylori and antibiotic resistance in fresh tissue reported as positive or negative, to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin


name: Next-generation sequencing of DNA, 16S, and 23S rRNA, gyrA, pbp1, rdxA, and rpoB for detection of Helicobacter pylori and for prediction of antibiotic resistance in formalin-fixed paraffin-embedded tissue sample, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin


name: Gene analysis for detection of ERBB2 (HER2) copy number variations associated with breast cancer using FISH in tumor cells from formalin-fixed paraffin-embedded tissue isolated by image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or nonamplified


name: Typing of bacterial strain by whole genome sequencing with phylogenetic-based report of strain relatedness, per submitted isolate


name: Prescription drug monitoring for presence of drug in oral fluid specimen using liquid chromatography-tandem mass spectrometry (LC-MS/MS)


name: DNA test for detecting gene abnormality associated with blood and lymphatic system cancer in blood or bone marrow


name: RNA test for detecting gene abnormality associated with blood and lymphatic system cancer in blood or bone marrow


name: RNA analysis for detection of BCR/ABL1 major and minor breakpoint fusion transcripts associated with hematolymphoid cancer using quantitative polymerase chain reaction (PCR) amplification in blood specimen, with report of fusion not detected or detected with quantitation


name: RNA analysis for detection of BCR/ABL1 major and minor breakpoint fusion transcripts associated with hematolymphoid cancer using quantitative polymerase chain reaction (PCR) amplification in bone marrow specimen, with report of fusion not detected or detected with quantitation


name: JAK2 mutation test for detecting gene abnormality associated with blood and lymphatic system cancer in blood or bone marrow


name: DNA analysis for detection of JAK2 mutation associated with hematolymphoid cancer by polymerase chain reaction (PCR) amplification of exons 12-14 and sequence analysis in blood specimen, with report


name: DNA analysis for detection of JAK2 mutation associated with hematolymphoid cancer by polymerase chain reaction (PCR) amplification of exons 12-14 and sequence analysis in bone marrow specimen, with report


name: Thyroid cancer microRNA profiling by reverse transcription polymerase chain reaction (RT-PCR) of 10 microRNA sequences in fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy


name: DNA genotyping of internal tandem duplication, p.D835, p.I836 in mononuclear cells for assessment of acute myelogenous leukemia, reported as detection or nondetection of FLT3 mutation and indication for or against the use of midostaurin


name: Quantitative measurement of glycosylated acute phase proteins (GlycA) using nuclear magnetic resonance spectroscopy


name: Quantitative measurement of tenofovir in urine using liquid chromatography-tandem mass spectrometry (LC-MS/MS)


name: DNA and mRNA next-generation sequencing of 112 genes with interrogation for sequence variants and rearrangements in fine needle aspirate of thyroid nodule for assessment of thyroid cancer, algorithmic analysis reported as a categorical result


name: Janus kinase 2 (JAK2) gene analysis, targeted sequence analysis, exons 12-15


name: Drug metabolism, targeted gene sequence analysis (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1, and rs12777823)


name: Warfarin drug response, targeted sequence analysis (CYP2C9, CYP4F2, VKORC1, and rs12777823)


name: Quantitative measurement of Vitamin D, 25 hydroxy D2, and D3 in serum microsample using liquid chromatography-tandem mass spectrometry (LC-MS/MS)


name: Quantitative major breakpoint translocation analysis of BCR/ABL1 (t(9;22))


name: IgM antibody detection test for Tick-Borne Relapsing Fever Borrelia group (IgM)


name: Detection of tick-borne relapsing fever (TBRF) Borrelia group IgM antibody to 4 recombinant protein groups using immunoblot


name: Detection of tick-borne relapsing fever (TBRF) Borrelia group IgG antibody to 4 recombinant protein groups using immunoblot


name: Breast ductal carcinoma in situ, mRNA gene expression profiling using real time reverse transcription polymerase chain reaction (RT-PCR) of 12 genes (7 content and 5 housekeeping) in formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score


name: Fms-related tyrosine kinase 3 (FLT3) quantitative gene analysis for internal tandem duplication (ITD) variants


name: Prostate cancer mRNA gene expression profiling using real time reverse transcription polymerase chain reaction (RT-PCR) of 17 genes (12 content and 5 housekeeping) in formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score


name: Solid organ neoplasia-targeted DNA sequencing of protein-coding exons of 468 cancer-associated genes with interrogation for somatic mutations and microsatellite instability, matched with normal specimens, in formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation


name: High resolution fractionation and quantitation of all 5 major lipoprotein classes and subclasses of high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL) in blood using vertical auto profile ultracentrifugation


name: Assay of cell-free DNA, polymerase chain reaction (PCR) of 96 DNA target sequences (94 single nucleotide polymorphism targets and 2 control targets) in plasma for assessment of heart transplant rejection


name: Quantitative detection of antibodies to Merkel cell polyoma virus oncoprotein in serum


name: Detection of antibodies to Merkel cell polyoma virus capsid protein (VP1) in serum


name: Genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood for detection of twin zygosity


name: Transcutaneous measurement of tissue oxygenation, oxyhemoglobin, deoxyhemoglobin, and papillary and reticular dermal hemoglobin concentrations using spatial frequency domain imaging and multispectral analysis


name: Measurement of 32 amines associated with autism spectrum disorder in serum by liquid chromatography-tandem mass spectrometry (LC-MS/MS), algorithm reported as metabolic signature associated with autism spectrum disorder


name: Detection of Treponema pallidum antibody by qualitative immunoassay using rapid plasma reagin (RPR)


name: Syphilis test by detection of non-treponemal antibody by qualitative immunoassay using rapid plasma reagin (RPR)


name: Colorectal cancer microRNA reverse transcription polymerase chain reaction (RT-PCR) gene expression profiling of miR-31-3p in formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score


name: Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) targeted gene sequence analysis of CYP2D7-2D7 hybrid gene


name: Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) targeted gene sequence analysis of CYP2D7-2D6 hybrid gene


name: Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) targeted gene sequence analysis of non-duplicated gene when duplication/multiplication is trans in targeted sequence


name: Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) 5' gene duplication/multiplication analysis of targeted sequence


name: Opioid-use disorder risk genotyping panel, 16 common variants (ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), in buccal swab, algorithm reported as positive or negative risk


name: Opioid-use disorder risk genotyping panel, 16 common variants (ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), in germline tissue sample, algorithm reported as positive or negative risk


name: Mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130 in plasma, with 5 clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), algorithm reported as a categorical probability of lung malignancy


name: Definitive drug testing for 90 or more drugs by definitive chromatography with mass spectrometry and presumptive drug testing for any number of drug classes, by instrument chemistry analyzer using immunoassay, in urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions, per date of service


name: Definitive drug testing for 90 or more substances by definitive chromatography with mass spectrometry and presumptive drug testing for any number of drug classes, by instrument chemistry analyzer using immunoassay, in urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions, per date of service


name: Melanoma mRNA gene expression profiling by reverse transcriptase quantitative polymerase chain reaction (RTqPCR) for PRAME and LINC00518 on superficial specimen collected using adhesive patch


name: Screening for colorectal cancer or adenoma by cell enumeration of circulating tumor cells in whole blood, algorithm reported as positive or negative


name: Prescription drug monitoring of 65 common drugs in urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS), each drug reported detected or not detected


name: Hereditary colon cancer disorders genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes sequencing for detection of deletion and duplication], EPCAM and GREM1 detection for deletion and duplication only)


name: Hereditary breast cancer-related disorders genomic sequence analysis panel utilizing a combination of next-generation sequencing (NGS), Sanger, multiplex ligation-dependent probe amplification (MLPA), and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes sequencing for detection of deletion and duplication)


name: Hereditary ovarian cancer genomic sequence analysis panel utilizing a combination of next-generation sequencing (NGS), Sanger, multiplex ligation-dependent probe amplification (MLPA), and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes sequencing for detection of deletion and duplication, epithelial cell adhesion molecule (EPCAM) deletion and duplication only)


name: Multiplex electrochemiluminescent immunoassay of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) in isolated fresh plasma, combined with longitudinal clinical data, algorithm reported as probability score for rapid kidney function decline (RKFD)


name: Multiplex electrochemiluminescent immunoassay of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) in isolated fresh plasma, combined with longitudinal clinical data, including APOL1 genotype, algorithm reported as probability score for rapid kidney function decline (RKFD)


name: Multiplex electrochemiluminescent immunoassay of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) in isolated frozen plasma, combined with longitudinal clinical data, algorithm reported as probability score for rapid kidney function decline (RKFD)


name: Multiplex electrochemiluminescent immunoassay of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) in isolated frozen plasma, combined with longitudinal clinical data, including APOL1 genotype, algorithm reported as probability score for rapid kidney function decline (RKFD)


name: Evaluation of gastric emptying by serial collection of 7 timed breath specimens after administration non-radioisotope carbon-13 (13C) spirulina substrate and analysis by gas isotope ratio mass spectrometry, reported as rate of 13 carbon dioxide (CO2) excretion


name: Detection of Clostridium difficile toxin antigen in stool by qualitative multiple-step method immunoassay


name: Whole slide digital imaging of esophageal cells in formalin-fixed paraffin-embedded tissue, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, algorithm reported as risk of progression to high-grade dysplasia or cancer


name: Real-time polymerase chain reaction (PCR) for detection of DNA from 4 Aspergillus species (Aspergillus fumigatus, Aspergillus terreus, Aspergillus niger, and Aspergillus flavus) in blood, qualitative reporting of presence or absence of each species


name: Real-time polymerase chain reaction (PCR) for detection of DNA from 4 Aspergillus species (Aspergillus fumigatus, Aspergillus terreus, Aspergillus niger, and Aspergillus flavus) in lavage fluid, qualitative reporting of presence or absence of each species


name: Real-time polymerase chain reaction (PCR) for detection of DNA from 4 Aspergillus species (Aspergillus fumigatus, Aspergillus terreus, Aspergillus niger, and Aspergillus flavus) in tissue, qualitative reporting of presence or absence of each species


name: Measurement of multiple oral oncology drugs by definitive tandem mass spectrometry with chromatography, in plasma from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of multiple oral oncology drugs by definitive tandem mass spectrometry with chromatography, in plasma from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of multiple oral oncology drugs by definitive tandem mass spectrometry with chromatography, in serum from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of multiple oral oncology drugs by definitive tandem mass spectrometry with chromatography, in serum from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of multiple oral oncology substances by definitive tandem mass spectrometry with chromatography, in plasma from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of multiple oral oncology substances by definitive tandem mass spectrometry with chromatography, in plasma from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of multiple oral oncology substances by definitive tandem mass spectrometry with chromatography, in serum from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of multiple oral oncology substances by definitive tandem mass spectrometry with chromatography, in serum from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology drug by definitive tandem mass spectrometry with chromatography, in plasma from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology drug by definitive tandem mass spectrometry with chromatography, in plasma from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology drug by definitive tandem mass spectrometry with chromatography, in serum from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology drug by definitive tandem mass spectrometry with chromatography, in serum from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in plasma from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in plasma from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in serum from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in serum from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis of colon cells for colon cancer in formalin-fixed paraffin-embedded tissue


name: Detection and identification of infectious agent by targeted gene sequence analysis (16S and 18S rRNA genes) with drug-resistance gene


name: Enzyme immunoassay of 35 or more drugs confirmed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications


name: Analysis of 11 endogenous agents (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid [3-HPMA], quinolinic acid, kynurenic acid), by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in urine, algorithm reported as pain-index score with likelihood of atypical biochemical function associated with pain


name: Measurement of ceramides by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in plasma, quantitative report with risk score for major cardiovascular events


name: Vacuum cell adhesion molecule (VCAM-1) microfluidic flow adhesion test in whole blood for sickle cell disease


name: Red blood cell (RBC) mechanical fragility test with shear stress and spectral analysis profiling


name: Hereditary breast cancer-related disorders genomic sequence analysis for detection of deletion and duplication analysis panel (including ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)


name: Hereditary colon cancer disorders targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53)


name: Hereditary ovarian cancer-related disorders targeted mRNA sequence analysis panel of 17 genes


name: Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel of 11 genes


name: Hereditary pan cancer targeted mRNA sequence analysis panel including 18 genes


name: Hereditary gynecological cancer-related disorders targeted mRNA sequence analysis panel of 12 genes


name: Partner and localizer of BRCA2 (PALB2) mRNA sequence analysis


name: BRCA1, (BRAC1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) mRNA sequence analysis


name: Amplifed DNA probe detection of fungus in blood culture specimen


name: Identification of fungal pathogen in blood culture specimen by DNA amplified probe technique, 15 fungal targets, reported as detected or not detected


name: Amplifed DNA probe detection of 20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, and 1 pan Candida target in blood culture specimen


name: Identification of gram-positive organism and detection of drug resistance element in blood culture specimen by DNA amplified probe technique, 20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target, reported as detected or not detected


name: Amplifed DNA probe detection of 20 gram-positive bacterial targets, 6 resistance genes, 1 pan gram-negative bacterial target, and 1 pan Candida target in blood culture specimen


name: Identification of gram-positive organism and detection of drug resistance element in blood culture by DNA amplified probe technique, 21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target, reported as detected or not detected


name: mRNA gene expression profiling of 101 genes in breast growth tissue specimen


name: mRNA gene expression profiling of breast cancer by real-time polymerase chain reaction (RT-PCR) and next-generation sequencing of 101 genes, algorithm reported as triple negative breast cancer clinical subtype with information on immune cell involvement


name: Oncology (urothelial cancer), RNA, analysis by real-time RT-PCR of the FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3), utilizing formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as FGFR gene alteration status


name: RNA gene analysis for detection of fibroblast growth factor receptor 3 gene alteration in urothelial tumor tissue specimen


name: RNA analysis of urothelial cancer by real-time polymerase chain reaction (RT-PCR) of fibroblast growth factor receptor 3 (FGFR3) gene, reported as FGFR gene alteration status


name: Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y), utilizing formalin-fixed paraffin-embedded breast tumor tissue, reported as PIK3CA gene mutation status


name: DNA analysis for detection of PIK3CA gene mutation in breast growth tissue specimen


name: DNA analysis of breast cancer by phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene analysis, reported as PIK3CA gene mutation status


name: Gene analysis copy number sequence analysis


name: mRNA gene analysis of APC regulator of WNT signaling pathway


name: APC regulator of WNT signaling pathway (APC) mRNA sequence analysis


name: MutL homolog 1 (MLH1) mRNA sequence analysis


name: MutS homolog 2 (MSH2) mRNA sequence analysis


name: MutS homolog 6 (MSH6) mRNA sequence analysis


name: mRNA gene analysis of PMS1 homolog 2, mismatch repair system component


name: PMS1 homolog 2 (PMS2 mismatch repair system component) mRNA sequence analysis


name: Targeted mRNA sequence analysis for genes associated with hereditary colon cancer


name: MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6), and PMS1 homolog 2 (PMS2 mismatch repair system component) targeted mRNA sequence analysis panel


name: Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas


name: Screening test for 3 protein biomarkers of colorectal cancer in serum or plasma specimen


name: Screening for colorectal cancer by biochemical enzyme-linked immunosorbent assay (ELISA) of teratocarcinoma derived growth factor-1 (TDGF-1, Cripto-1), carcinoembryonic antigen (CEA), and extracellular matrix protein (ECM), with demographic data, algorithm reported as likelihood of colorectal cancer or advanced adenomas


name: Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results


name: Test for detection of antibodies associated with irritable bowel syndrome in plasma specimen, reported as elevated or not elevated


name: Immunoassay for inflammatory bowel-associated antibodies anti-cytolethal distending toxin B (CdtB) and anti-vinculin antibodies in plasma specimen, algorithm reported as elevated or not elevated


name: Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy


name: Test for detection of antigens associated with peanut allergy in blood specimen, reported as probability of peanut allergy


name: Measurement of multiple peanut allergen-specific epitopes in blood specimen by enzyme-linked immunosorbent assay (ELISA), reported as individual epitope results and probability of peanut allergy


name: Liver disease, 10 biochemical assays (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation


name: Liver disease test panel in serum specimen


name: Biochemical assay for 10 markers of liver disease (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma-glutamyl transferase [GGT], alanine aminotransferase [ALT], aspartate aminotransferase [AST], triglycerides, cholesterol, and fasting glucose) in serum specimen, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with summary interpretation


name: Gonadotropin, chorionic (hCG), immunoassay with direct optical observation, blood


name: Test for detection of human chorionic gonadotropin (pregnancy hormone) in blood specimen


name: Immunoassay for chorionic gonadotropin (hCG) in blood specimen with direct optical observation of result


name: NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants


name: Gene analysis (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) for detection of common variants


name: Nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) gene analysis for detection of common variants


name: Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis


name: RNA gene sequencing for probability of autism spectrum disorder in saliva specimen


name: Next-generation RNA sequencing of genes associated with autism spectrum disorder in saliva specimen, algorithm reported as predictive probability of autism spectrum disorder


name: Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence


name: DNA analysis of targeted sequences in 23 genes for detection of abnormalites associated with myeloid leukemia, myelodysplastic syndrome, and myeloproliferative cancer


name: Targeted DNA sequence analysis panel of 23 genes for detection of abnormalities associated with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, reported as presence/absence


name: Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score


name: DNA gene analysis (BRCA1, DNA repair associated and BRCA2, DNA repair associated) for detection of mutations associated with breast cancer


name: Somatic mutation analysis of BRCA1, DNA repair associated (BRCA1) and BRCA2 (BRCA2, DNA repair associated) and DNA analysis of homologous recombination deficiency pathways in breast tumor tissue specimen, algorithm reported as tumor genomic instability score


name: Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes


name: Gene analysis panel for detection of variants in 14 genes associated with psychiatric disorders


name: Genomic analysis panel of 14 genes for detection of variants associated with psychiatric disorder


name: Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents


name: Mass spectrometry testing for 30 protein targets in tissue specimen to predict benefit of cancer therapy agents


name: Evaluation of 30 protein targets in tumor tissue specimen by mass spectometry, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents


name: Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes


name: Gene analysis panel for detection of variants in 15 genes associated with psychiatric disorders


name: Genomic analysis panel of 15 genes for detection of variants associated with psychiatric disorder


name: Test for detection of IgG antibodies associated with irritable bowel syndrome


name: Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status


name: DNA gene analysis (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) for detection of mutations associated with breast cancer


name: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) DNA gene analysis of 11 gene variants in plasma specimen, reported as PIK3CA gene mutation status


name: Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction


name: Test for detection of antigens associated with peanut allergy in blood specimen, reported as minimum exposure for clinical reaction


name: Measurement of multiple peanut allergen-specific epitopes by enzyme-linked immunosorbent assay (ELISA) in blood specimen, report of minimum eliciting exposure for clinical reaction


name: Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)


name: Cell-free DNA analysis of targeted sequences in 23 genes for detection of mutations associated with non-small cell lung cancer


name: Targeted sequence analysis of 23 genes in cell-free DNA specimen for significant mutation


name: Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons


name: Red blood cell antigen genotyping, ABO blood group


name: ABO blood group red cell antigen genotyping, ABO alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) Sanger/chain termination/conventional sequencing of 7 exons, including subtyping


name: Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1


name: Red blood cell antigen genotyping, Colton blood group


name: Colton blood group red cell antigen genotyping (CO), aquaporin 1 (Colton blood group) (AQP1) gene analysis of exon 1


name: Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10


name: Red blood cell antigen genotyping, CD55 molecule [Cromer blood group] exons 1-10


name: Cromer blood group red cell antigen genotyping (CROM), CD55 molecule (Cromer blood group) (CD55) gene analysis of exons 1-10


name: Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19


name: Red blood cell antigen genotyping, solute carrier family 4 member 1 [Diego blood group] exon 19


name: Diego blood group red cell antigen genotyping (DI), solute carrier family 4 member 1 (Diego blood group) (SLC4A1) gene analysis of exon 19


name: Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2


name: Red blood cell antigen genotyping, ADP-ribosyltransferase 4 [Dombrock blood group] exon 2


name: Dombrock blood group red cell antigen genotyping (DO), ADP-ribosyltransferase 4 (Dombrock blood group) (ART4) gene analysis of exon 2


name: Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4


name: Red blood cell antigen genotyping, fucosyltransferase 1 [H blood group] exon 4


name: H blood group red cell antigen genotyping (FUT1), fucosyltransferase 1 (H blood group) (FUT1) gene analysis of exon 4


name: Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2


name: Red blood cell antigen genotyping, fucosyltransferase 2 [H blood group] exon 2


name: H blood group red cell antigen genotyping (FUT2), fucosyltransferase 2 (H blood group) (FUT2) gene analysis of exon 2


name: Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2


name: Red blood cell antigen genotyping, atypical chemokine receptor 1 [Duffy blood group] exons 1-2


name: Duffy blood group red cell antigen genotyping (FY), atypical chemokine receptor 1 (Duffy blood group) (ACKR1) gene analysis of exons 1-2


name: Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4


name: Red blood cell antigen genotyping, glycophorin C [Gerbich blood group] exons 1-4


name: Gerbich blood group red cell antigen genotyping (GE), glycophorin C (Gerbich blood group) (GYPC) gene analysis of exons 1-4


name: Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2


name: Red blood cell antigen genotyping, glycophorin A [MNS blood group] introns 1, 5, exon 2


name: MNS blood group blood group red cell antigen genotyping (GYPA), glycophorin A (MNS blood group) (GYPA) gene analysis of introns 1, 5, exon 2


name: Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3


name: Red blood cell antigen genotyping, glycophorin B [MNS blood group] introns 1, 5, pseudoexon 3


name: MNS blood group blood group red cell antigen genotyping (GYPB), glycophorin B (MNS blood group) (GYPB) gene analysis of introns 1, 5, pseudoexon 3


name: Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6


name: Red blood cell antigen genotyping, CD44 molecule [Indian blood group] exons 2, 3, 6


name: Indian blood group red cell antigen genotyping (IN), CD44 molecule (Indian blood group) (CD44) gene analysis of exons 2, 3, 6


name: Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9


name: Red blood cell antigen genotyping, solute carrier family 14 member 1 [Kidd blood group] gene promoter, exon 9solute carrier family 14 member 1 [Kidd blood group] gene promoter, exon 9


name: Kidd blood group red cell antigen genotyping (JK), solute carrier family 14 member 1 (Kidd blood group) (SLC14A1) gene analysis of exon 9


name: Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26


name: Red blood cell antigen genotyping, ATP binding cassette subfamily G member 2 [Junior blood group] exons 2-26


name: JR blood group red cell antigen genotyping (JR), ATP binding cassette subfamily G member 2 (Junior blood group) (ABCG2) gene analysis of exons 2-26


name: Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8


name: Red blood cell antigen genotyping, Kell metallo-endopeptidase [Kell blood group] exon 8


name: Kell blood group red cell antigen genotyping (KEL), Kell metallo-endopeptidase (Kell blood group) (KEL) gene analysis of exon 8


name: KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)


name: Gene analysis (Kruppel-like factor 1) targeted sequence analysis


name: Kruppel-like factor 1 (KLF1) gene analysis of targeted sequence


name: Kruppel-like factor 1 (KLF1) targeted sequence analysis of exon 13


name: Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3


name: Red blood cell antigen genotyping, basal cell adhesion molecule [Lutheran blood group] exon 3


name: Lutheran blood group red cell antigen genotyping (LU), basal cell adhesion molecule (Lutheran blood group) (BCAM) gene analysis of exon 3


name: Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1


name: Red blood cell antigen genotyping, intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]


name: Landsteiner-Wiener blood group red cell antigen genotyping (LW), intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) (ICAM4) gene analysis of exon 1


name: Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5


name: Red blood cell antigen genotyping, Rh blood group D antigen exons 1-10 and Rh blood group CcEe antigens exon 5


name: RH blood group red cell antigen genotyping (RHD and RHCE), Rh blood group D antigen (RHD) Sanger/chain termination/conventional sequencing of exons 1-10 and Rh blood group CcEe antigens (RHCE) exon 5


name: Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12


name: Red blood cell antigen genotyping, erythroblast membrane associated protein [Scianna blood group] exons 4, 12


name: Scianna blood group red cell antigen genotyping (SC), erythroblast membrane associated protein (Scianna blood group) (ERMAP) gene analysis of exons 4, 12


name: Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3


name: Red blood cell antigen genotyping, X-linked Kx blood group exons 1-3


name: Kx blood group red cell antigen genotyping (XK), X-linked Kx blood group) (XK) gene analysis of exons 1-3


name: Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2


name: Red blood cell antigen genotyping, acetylcholinesterase [Cartwright blood group] exon 2


name: Yt blood group red cell antigen genotyping (YT), (Acetylcholinesterase (Cartwright blood group) (ACHE) gene analysis of exon 2


name: Test for detection of respiratory disease-causing organisms from back of nose and throat (nasopharynx) specimen, 22 target organisms including severe acute respiratory syndrome coronavirus 2


name: Detection of pathogen-specific nucleic acid in nasopharyngeal swab specimen by qualitative real-time polymerase chain reaction (RT-PCR), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), each pathogen reported as detected or not detected


name: Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness


name: mRNA gene expression profiling of 17 genes in whole blood specimen for evaluation of inflammatory bowel disease


name: mRNA gene expression profiling by quantitative real-time polymerase chain reaction (RT-PCR), 17 genes (15 target and 2 reference genes) in whole blood specimen, reported as continuous risk score and classification of inflammatory bowel disease aggressiveness


name: Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected


name: mRNA gene analysis of 539 genes in fine needle aspiration thyroid specimen, reported as detected or not detected


name: mRNA gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements in fine needle aspirate thyroid specimen, reported as detected or not detected


name: Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements


name: Gene analysis for detection of variants in 3 genes in cheek swab specimen for neovascular age-related macular-degeneration risk associated with zinc supplements


name: Gene analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using polymerase chain reaction (PCR) and matrix-assisted laser desorption ionization time of flight (MALDI-TOF) in buccal swab specimen, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements


name: Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease


name: Cell aggregation testing of cultured skin cells for Alzheimer disease, reported as positive or negative for Alzheimer disease


name: Cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by enzyme-linked immunosorbent assay (ELISA), in cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease


name: Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)


name: Immunofluorescence testing of cultured skin cells for Alzheimer disease, reported as probability index for Alzheimer disease


name: Quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as probability index for Alzheimer disease


name: Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities


name: Cytogenomic analysis of whole genome for abnormal chromosomes


name: Cytogenomic constitutional analysis with interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities


name: Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR)


name: Measurement of nontreponemal antibodies associated with syphilis


name: Syphilis test by detection of non-treponemal antibody by immunoassay using rapid plasma reagin (RPR)


name: Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association


name: Next-generation sequencing of DNA and RNA in tumor tissue specimen with interpretative report


name: Next-generation DNA and RNA sequencing in tissue specimen, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association


name: Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband


name: Rare diseases genetic testing of complete DNA of first affected person in family


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from proband


name: Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling)


name: Rare diseases genetic testing of complete DNA of relative of affected person in family


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator blood sample from parent of proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator blood sample from relative of proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator blood sample from sibling of proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator saliva sample from relative of proband


name: Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband


name: Rare diseases genetic testing of protein coding genes of first affected person in family


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from proband


name: Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)


name: Rare diseases genetic testing of protein coding genes of relative of affected person in family


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from parent of proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from relative of proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from parent of proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from relative of proband


name: Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants


name: DNA analysis of gene sequence of 12 genes for identification and characterization of abnormalites associated with inherited disorders of movement (ataxia)


name: Genomic DNA sequence of 12 common genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood specimen, with identification and categorization of genetic variants


name: Genomic DNA sequence of 12 common genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva specimen, with identification and categorization of genetic variants


name: Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants


name: DNA analysis of gene sequence of 51 genes for identification and characterization of abnormalites associated with inherited disorders of movement (ataxia)


name: Genomic DNA sequence of 51 genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood specimen, with identification and categorization of genetic variants


name: Genomic DNA sequence of 51 genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva specimen, with identification and categorization of genetic variants


name: Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants


name: DNA analysis of gene sequence for identification and characterization of abnormalites associated with muscular dystrophy


name: Duschenne muscular dystrophy (DMD gene sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood specimen, with identification and categorization of genetic variants


name: Duschenne muscular dystrophy (DMD gene sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva specimen, with identification and categorization of genetic variants


name: Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility


name: Gene analysis of human immunodeficiency virus targeted sequence analysis for resistance to antiviral drugs


name: Targeted next-generation protease (PR), reverse transcriptase (RT), integrase (INT) sequence analysis of human immunodeficiency virus, algorithm reported as prediction of antiviral drug susceptibility


name: Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score


name: Image analysis of breast cancer cell specimen with artificial intelligence assessment


name: Image analysis of breast cancer with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as recurrence score


name: Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene


name: Red blood cell antigen genotyping, ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase gene next generation sequencing


name: ABO blood group red cell antigen genotyping, ABO alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) next-generation sequencing


name: Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3


name: Red blood cell antigen genotyping, RH proximal promoter, exons 1-10, portions of introns 2-3


name: RH blood group red cell antigen genotyping (RHD and RHCE), next-generation sequencing of RH proximal promoter, exons 1-10, portions of introns 2-3


name: Detection of respiratory tract pathogen nucleic acid in nasopharyngeal swab specimen by qualitative real-time polymerase chain reaction (TR-PCR), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), each pathogen reported as detected or not detected


name: Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed


name: Measurement of antibody to severe acute respiratory syndrome coronavirus 2 (COVID-19)


name: Measurement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody, including titers


name: Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected


name: Test for detection of respiratory disease-causing organisms, 21 target organisms including severe acute respiratory syndrome coronavirus 2 (COVID-19)


name: Detection of respiratory disease infectious agent DNA and RNA, 21 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by amplified probe technique with multiplex reverse transcription for RNA targets, reported as detected or not detected


name: Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum


name: Surrogate viral neutralization test (sVNT) for detection of antibodies to severe acute respiratory syndrome coronavirus 2 (Covid-19) by


name: Surrogate viral neutralization test (sVNT) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in plasma specimen by enzyme-linked immunosorbent assay (ELISA)


name: Surrogate viral neutralization test (sVNT) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in serum specimen by enzyme-linked immunosorbent assay (ELISA)


name: Administration of first or only component of each toxoid via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of first or only component of each toxoid via any route with counseling by physician, patient 18 years of age or younger


name: Administration of first or only component of each vaccine via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of first or only component of each vaccine via any route with counseling by physician, patient 18 years of age or younger


name: Administration of each additional toxoid component via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of each additional toxoid component via any route with counseling by physician, patient 18 years of age or younger


name: Administration of each additional vaccine component via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of each additional vaccine component via any route with counseling by physician, patient 18 years of age or younger


name: Intranasal administration of each additional combination toxoid


name: Intranasal administration of each additional combination vaccine


name: Intranasal administration of each additional single toxoid


name: Intranasal administration of each additional single vaccine


name: Intraoral administration of each additional combination toxoid


name: Intraoral administration of each additional combination vaccine


name: Intraoral administration of each additional single toxoid


name: Intraoral administration of each additional single vaccine


name: Adenovirus vaccine, type 4, live, for oral use (procedure)


name: Adenovirus vaccine, type 7, live, for oral use (procedure)


name: Live Bacillus Calmette-Guerin (BCG) vaccine, for percutaneous use


name: Live Bacillus Calmette-Guerin (BCG) vaccine, for intravesical use


name: Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 dose schedule, for intramuscular use


name: Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 3 dose schedule, for intramuscular use


name: Cholera vaccine, adult dosage, single dose schedule, for oral use


name: Hepatitis A (HepA) vaccine, adolescent dosage, 2 dose schedule, for intramuscular use


name: Hepatitis A (HepA) vaccine, pediatric dosage, 2 dose schedule, for intramuscular use


name: Hepatitis A (HepA) vaccine, adolescent dosage, 3 dose schedule, for intramuscular use


name: Hepatitis A (HepA) vaccine, pediatric dosage, 3 dose schedule, for intramuscular use


name: Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 58, nonavalent (9vHPV), 2 dose schedule, for intramuscular use


name: Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 58, nonavalent (9vHPV), 3 dose schedule, for intramuscular use


name: Inactivated adjuvanted influenza virus vaccine(IIV), for intramuscular use


name: Influenza virus vaccine, derived from cell cultures, subunit, preservative and antibiotic free, trivalent (ccIIV3), for intramuscular use


name: Influenza vaccine, quadrivalent for nasal administration


name: Live preservative-free influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, for intramuscular use


name: Diphtheria and tetanus (DT) toxoids adsorbed, patient younger than 7 years of age, for intramuscular use


name: Inactivated poliovirus vaccine (IPV), for intramuscular use


name: Inactivated poliovirus vaccine (IPV), for subcutaneous use


name: Preservative free tetanus and diphtheria (Td) adsorbed toxoids, patient 7 years of age or older, for intramuscular use


name: Diphtheria, tetanus toxoids, and acellular pertussis (Tdap) vaccine, patient 7 years of age or older


name: Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, patient 2 years of age or older, for intramuscular use


name: Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, patient 2 years of age or older, for subcutaneous use


name: Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 quadrivalent (MCV4 or MenACWY), for intramuscular use


name: Hepatitis B (HepB) vaccine, dialysis patient dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, immunosuppressed patient dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, adolescent dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, pediatric dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, dialysis patient dosage, 4 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, immunosuppressed patient dosage, 4 dose schedule, for intramuscular use


name: Psychotherapy with evaluation and management visit, 45 minutes


name: Psychotherapy for crisis, each additional 30 minutes


name: Family psychotherapy with patient present, 50 minutes


name: Pharmacological management with prescription and review of medication, and psychotherapy service


name: Narcosynthesis for psychiatric diagnostic and therapeutic purposes


name: Initial delivery and management of therapeutic repetitive transcranial magnetic stimulation (TMS) treatment with cortical mapping and motor threshold determination


name: Subsequent delivery and management of therapeutic repetitive transcranial magnetic stimulation (TMS) treatment, per session


name: Subsequent motor threshold redetermination with delivery and management of therapeutic repetitive transcranial magnetic stimulation (TMS) treatment


name: Individual psychophysiological therapy incorporating biofeedback training by any modality, face-to-face with the patient, with psychotherapy, 30 minutes


name: Individual psychophysiological therapy incorporating biofeedback training by any modality, face-to-face with the patient, with psychotherapy, 45 minutes


name: Biofeedback training of anorectal sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG), initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG), initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter with manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG) and manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG) and manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG), initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG), initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles with manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG), initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG), initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter with manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG) and manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG), each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG) and manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG), each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG), each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with with electromyography (EMG) and manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Hemodialysis procedure with single evaluation by other qualified health care professional


name: Dialysis procedure (other than hemodialysis) with single evaluation by other qualified health care professional


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age, with single face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age, with single face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age, with 1 face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older, with single face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient younger than 2 years of age


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient 2-11 years of age


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient 12-19 years of age


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient 20 years of age or older


name: Dialysis training including helper, completed course


name: Dialysis training including helper, course not completed


name: Gastroesophageal junction study with perfusion, with interpretation and report


name: Gastroesophageal junction study with stimulation, with interpretation and report


name: Manometric study of the esophagus and gastroesophageal junction study with perfusion, with interpretation and report


name: Manometric study of the esophagus and gastroesophageal junction study with stimulation, with interpretation and report


name: Manometric study of the esophagus with perfusion, with interpretation and report


name: Manometric study of the esophagus with stimulation, with interpretation and report


name: Prolonged (more than 1 hour, less than 24 hours) gastroesophageal reflux test of esophagus with nasal catheter intraluminal impedance electrodes placement, recording, analysis and interpretation


name: Diagnostic esophageal balloon distension provocation study


name: Diagnostic esophageal balloon distension study


name: Intraluminal gastrointestinal tract imaging of esophagus through ileum, with interpretation and report


name: Intraluminal gastrointestinal tract imaging of esophagus with interpretation and report


name: Gastrointestinal tract transit and pressure measurement from stomach to colon using wireless capsule with interpretation and report


name: Colon manometric study with provocation tests, minimum of 6 hours continuous reading with interpretation and report


name: New patient ophthalmological intermediate medical examination and evaluation with initiation of diagnostic and treatment program


name: Ophthalmological comprehensive medical examination and initiation of diagnostic and treatment program for new patient, multiple visits


name: Ophthalmological comprehensive medical examination and initiation of diagnostic and treatment program for new patient, single visit


name: Ophthalmological intermediate medical examination and continuation of diagnostic and treatment program for established patient